Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
RXRX Recursion Pharmaceuticals
9.100-0.540-5.60%
Close
02/06 16:00 ET
9.1000.0000.00%
Post Mkt Price 02/06 16:01 ET
High
9.730
Open
9.570
Turnover
6.54M
Low
9.040
Pre Close
9.640
Volume
711.99K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Insider Sell: Recursion Pharmaceuticals
05:16 PM EST, 02/03/2023 (MT Newswires) -- Christopher Gibson, Director, Chief Executive Officer, on February 01, 2023, sold 21,000 shares in Recursion Pharmaceuticals (RXRX) for $193,561. Following t
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by SG Americas Securities LLC
SG Americas Securities LLC lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 54.2% during the 3rd quarter, according to its most recent 13F filing with the Securit
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating
07:45 AM EST, 02/02/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Berenberg Bank Keeps Their Buy Rating on Recursion Pharmaceuticals (RXRX)
Recursion to Participate in Upcoming Investor Conference
Tina Marriott Larson Sells 8,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, January 26th. The
Mubadala Investment Co Pjsc Acquires 24,526 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) major shareholder Mubadala Investment Co Pjsc bought 24,526 shares of the business's stock in a transaction that occurred on Wednesday, Janu
DekaBank Deutsche Girozentrale Acquires 21,500 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
DekaBank Deutsche Girozentrale lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 55.8% in the 3rd quarter, according to the company in its most recent filing with
Shareholders in Recursion Pharmaceuticals (NASDAQ:RXRX) Have Lost 24%, as Stock Drops 5.3% This Past Week
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders should be happy to see the share price up 14% in the last month. But that is minimal compensation for the share price under-performance ov
Blake Borgeson Sells 8,885 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the business's stock in a transaction that occurred on Tuesday, January 24th. The stock was sol
Company Overview
More
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
CEO： Dr. Christopher Gibson, PhD
Market： NASDAQ
Listing Date： 04/16/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet